XSHG
603520
Market cap559mUSD
Oct 09, Last price
8.72CNY
1D
1.99%
1Q
-9.54%
Jan 2017
-50.06%
IPO
24.22%
Name
Zhejiang Starry Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Founded in 1997 and headquartered in Xianju, China, Zhejiang Starry Pharmaceutical Co.,Ltd. specializes in the research, production, and global distribution of X-CT non-ionic contrast agents and fluoroquinolone pharmaceuticals, along with their key intermediates. The company's extensive range of contrast agent products includes iohexol (and its hydrolysate and iodide derivatives), ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate. For fluoroquinolones, their offerings feature levofloxacin (and its hydrochloride salt), levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate.
Key people
Jinsheng Hu
Chairman of the Board · since 2018
Jian Hu
Vice Chairman of the Board, General Manager · since 2018
Zhihua Jiang
Deputy General Manager
Pengcheng Liu
Deputy General Manager · since 2017
Jinwei Wu
Deputy General Manager, Director
Chuanlong Xu
Deputy General Manager
Fei Yuan
Deputy General Manager
Chaoqun Wu
Secretary of the Board · since 2017
Qinhu Fang
Deputy General Manager, Director
Jinrong Li
Director
Wenhao Hu
Independent Director
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||